Gland Pharma [GLAND] vs Syngene [SYNGENE] Detailed Stock Comparison

Gland Pharma Ltd.

NSE
Loading...

Syngene International Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Gland Pharma Ltd. wins in 13 metrics, Syngene International Ltd. wins in 7 metrics, with 0 ties. Gland Pharma Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Gland Pharma Ltd. Syngene International Ltd. Better
P/E Ratio (TTM) 34.86 48.19 Gland Pharma Ltd.
Price-to-Book Ratio 3.09 3.57 Gland Pharma Ltd.
Debt-to-Equity Ratio 3.16 12.28 Gland Pharma Ltd.
PEG Ratio 0.58 -0.56 Gland Pharma Ltd.
EV/EBITDA 18.80 16.28 Syngene International Ltd.
Profit Margin (TTM) 13.86% 9.47% Gland Pharma Ltd.
Operating Margin (TTM) 19.30% 12.94% Gland Pharma Ltd.
EBITDA Margin (TTM) 19.30% 12.94% Gland Pharma Ltd.
Return on Equity 7.63% 10.50% Syngene International Ltd.
Return on Assets (TTM) 6.22% 7.30% Syngene International Ltd.
Free Cash Flow (TTM) $5.21B $3.98B Gland Pharma Ltd.
Dividend Yield 1.95% 0.39% Gland Pharma Ltd.
1-Year Return 33.88% -29.79% Gland Pharma Ltd.
Price-to-Sales Ratio (TTM) 4.84 4.55 Syngene International Ltd.
Enterprise Value $266.81B $151.62B Gland Pharma Ltd.
EV/Revenue Ratio 4.37 4.08 Syngene International Ltd.
Gross Profit Margin (TTM) 65.99% 74.99% Syngene International Ltd.
Revenue per Share (TTM) $371 $92 Gland Pharma Ltd.
Earnings per Share (Diluted) $51.50 $8.74 Gland Pharma Ltd.
Beta (Stock Volatility) 0.41 -0.16 Syngene International Ltd.

Gland Pharma Ltd. vs Syngene International Ltd. Stock Performance Analysis

Loading Price Chart...

GLAND
SYNGENE

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Gland Pharma Ltd.-2.31%-1.82%18.29%37.34%32.35%28.86%
Syngene International Ltd.-1.10%0.89%-0.12%10.57%-31.32%-30.25%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Gland Pharma Ltd.33.88%124.19%-26.40%24.33%24.33%24.33%
Syngene International Ltd.-29.79%-38.23%-19.99%131.38%186.56%186.56%

Performance & Financial Health Analysis: Gland Pharma Ltd. vs Syngene International Ltd.

MetricGLANDSYNGENE
Market Information
Market Cap i₹295.80B₹169.26B
Market Cap CategoryLarge capMid cap
10 Day Avg. Volume i98,026970,201
90 Day Avg. Volume i91,7821,503,323
Last Close₹2,210.00₹453.50
52 Week Range₹1,573.60 - ₹2,396.00₹380.00 - ₹728.60
% from 52W High-7.76%-37.76%
All-Time High₹4,350.00 (Aug 09, 2021)₹960.60 (Dec 02, 2024)
% from All-Time High-49.20%-52.79%
Growth Metrics
Quarterly Revenue Growth0.23%-0.03%
Quarterly Earnings Growth0.28%-0.89%
Financial Health
Profit Margin (TTM) i0.14%0.09%
Operating Margin (TTM) i0.19%0.13%
Return on Equity (TTM) i0.08%0.11%
Debt to Equity (MRQ) i3.1612.28
Cash & Liquidity
Book Value per Share (MRQ)₹580.47₹117.84
Cash per Share (MRQ)₹194.34₹29.82
Operating Cash Flow (TTM) i₹7.50B₹5.00B
Levered Free Cash Flow (TTM) i₹6.99B₹4.96B
Dividends
Last 12-Month Dividend Yield i1.95%0.39%
Last 12-Month Dividend i₹38.00₹2.50

Valuation & Enterprise Metrics Analysis: Gland Pharma Ltd. vs Syngene International Ltd.

MetricGLAND (Apr 24, 2026)SYNGENE (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i34.8648.19
Forward P/E i25.0337.12
PEG Ratio i0.58-0.56
Price to Sales (TTM) i4.844.55
Price to Book (MRQ) i3.093.57
Market Capitalization
Market Capitalization i₹295.80B₹169.26B
Enterprise Value i₹266.81B₹151.62B
Enterprise Value Metrics
Enterprise to Revenue i4.374.08
Enterprise to EBITDA i18.8016.28
Risk & Other Metrics
Beta i0.41-0.16
Book Value per Share (MRQ) i₹580.47₹117.84

Financial Statements Comparison: Gland Pharma Ltd. vs Syngene International Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGLAND (2025)SYNGENE (2025)
Revenue/Sales i55.84B35.13B
Cost of Goods Sold i20.90B9.43B
COGS % of Revenue i37.4%26.8%
Gross Profit i34.93B25.70B
Gross Margin i62.6%73.2%
Research & Development i332.84MN/A
Operating Income (EBIT) i8.90B6.14B
Operating Margin i15.9%17.5%
EBITDA i14.76B10.96B
EBITDA Margin i26.4%31.2%
Pre-Tax Income i10.63B6.60B
Pre-Tax Income % of Revenue i19.0%18.8%
Income Tax i3.64B1.64B
Income Tax % of Revenue i6.5%4.7%
Net Income (Profit) i6.99B4.96B
Profit Margin i12.5%14.1%

Balance Sheet & Liquidity Metrics

MetricGLAND (2025)SYNGENE (2025)
Cash & Equivalents i25.56B3.67B
Total Current Assets i67.83B22.87B
Total Current Assets % of Revenue i121.5%65.1%
Total Current Liabilities i15.65B13.96B
Total Current Liabilities % of Revenue i28.0%39.8%
Long-Term Debt i1.07B4.09B
Long-Term Debt % of Revenue i1.9%11.6%
Total Shareholders Equity i91.51B47.27B
Retained Earnings i71.57B38.82B
Retained Earnings % of Revenue i128.2%110.5%
Property, Plant & Equipment i3.59B27.42B

Cash Flow Statement Comparison

MetricGLAND (2025)SYNGENE (2025)
Operating Cash Flow i7.50B5.00B
Operating Cash Flow % of Revenue i13.4%14.2%
Capital Expenditures i-3.84B-7.60B
Free Cash Flow i5.21B3.98B
FCF Margin i9.3%11.3%
Debt Repayment i-628.24M-417.00M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLANDSYNGENE
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i164.76M401.75M
Float Shares i79.36M159.12M
% Held by Insiders i51.84%53.09%
% Held by Institutions i36.58%37.28%
% Held by Public i11.58%9.63%

Dividend Analysis & Yield Comparison: Gland Pharma Ltd. vs Syngene International Ltd.

MetricGLANDSYNGENE
Last 12-Month Dividend i₹38.00₹2.50
Last 12-Month Dividend Yield i1.95%0.39%
3-Year Avg Annual Dividend i₹12.67₹1.25
3-Year Avg Dividend Yield i1.00%0.14%
3-Year Total Dividends i₹38.00₹3.75
Ex-Dividend DateAug 14, 2025Jun 27, 2025